madman
Super Moderator
Conclusion:
- male hypogonadism associated with obesity is very prevalent and is increasing in parallel to the increasing prevalence of obesity
- hypogonadism perpetuates obesity, especially central obesity and, as a consequence, related cardiometabolic complications, such as T2DM and cardiovascular disease
- the importance of hypogonadism as a comorbidity of obesity in men is gradually becoming clear
- our review enabled us to conclude that screening for the presence of hypogonadism is advisable in obese men, especially in those with T2DM
- in addition, despite changes in lifestyle to achieve significant weight loss should be the basis of treatment, in some cases, testosterone therapy may be indicated, as in those men with multiple signs and symptoms of hypogonadism an concomitant reduced levels of testosterone
- in obese men with hypogonadism, this treatment has shown to improve body composition and to have beneficial effects on metabolic risk factors and the underlying pathophysiological mechanisms
- its use has not been shown to increase the risk of cardiovascular events in this population
- the presence of hypogonadism associated with obesity should be taken into account when establishing the indication for bariatric surgery
- randomized controlled clinical trials are needed to reinforce the available evidence
-
- male hypogonadism associated with obesity is very prevalent and is increasing in parallel to the increasing prevalence of obesity
- hypogonadism perpetuates obesity, especially central obesity and, as a consequence, related cardiometabolic complications, such as T2DM and cardiovascular disease
- the importance of hypogonadism as a comorbidity of obesity in men is gradually becoming clear
- our review enabled us to conclude that screening for the presence of hypogonadism is advisable in obese men, especially in those with T2DM
- in addition, despite changes in lifestyle to achieve significant weight loss should be the basis of treatment, in some cases, testosterone therapy may be indicated, as in those men with multiple signs and symptoms of hypogonadism an concomitant reduced levels of testosterone
- in obese men with hypogonadism, this treatment has shown to improve body composition and to have beneficial effects on metabolic risk factors and the underlying pathophysiological mechanisms
- its use has not been shown to increase the risk of cardiovascular events in this population
- the presence of hypogonadism associated with obesity should be taken into account when establishing the indication for bariatric surgery
- randomized controlled clinical trials are needed to reinforce the available evidence
-
